Literature DB >> 8276053

Dextromethorphan O-demethylation polymorphism in Jordanians.

Y M Irshaid1, H F al-Hadidi, N M Rawashdeh.   

Abstract

The O-demethylation of dextromethorphan (DMT) to dextrorphan (DRP) was studied in 241 unrelated, healthy Jordanian volunteers (171 males, 70 females). Urine was collected for 8 h following a single oral dose of DMT bromhydrate 30 mg. A thin-layer chromatographic (TLC) technique was used to identify the metaboliser phenotype. The frequency of the poor metaboliser phenotype was found to be 2.9% (approximate 95% confidence interval 0.8-5.0%). Applying the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling poor metabolism was 0.17 (95% confidence interval 0.108-0.232).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276053     DOI: 10.1007/bf00315395

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

2.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Authors:  D Larrey; G Babany; M Tinel; E Freneaux; G Amouyal; F Habersetzer; P Letteron; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.

Authors:  K Brøsen; T Zeugin; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1991-06       Impact factor: 6.875

6.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man.

Authors:  T Wang; D M Roden; H T Wolfenden; R L Woosley; A J Wood; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

Authors:  F Broly; C Libersa; M Lhermitte; P Bechtel; B Dupuis
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

9.  Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

Authors:  M Hildebrand; W Seifert; A Reichenberger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism.

Authors:  R J Guttendorf; P J Wedlund; J Blake; S L Chang
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

View more
  3 in total

1.  Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province).

Authors:  Mohammad Reza Shiran; Fatemeh Sarzare; Fatemeh Merat; Ebrahim Salehifar; Ali Akbar Moghadamnia; Seyed Mohammad Bagher Hashemi Soteh
Journal:  Caspian J Intern Med       Date:  2011

2.  Dextromethorphan metabolic phenotyping in an Iranian population.

Authors:  Minoo Afshar; Mohammadreza Rouini; Shahram Ala
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.

Authors:  Y M Irshaid; H F al-Hadidi; A Latif; F Awwadi; M al-Zoubi; N M Rawashdeh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.